- Home
- ATXI
as 07-26-2024 4:00pm EST
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BAY HARBOR ISLANDS |
| Market Cap: | 3.3M | IPO Year: | 2017 |
| Target Price: | $56.25 | AVG Volume (30 days): | 80.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $82.50 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Avenue Therapeutics Inc. (ATXI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 264,000 | $36,960.00 | 681,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.15 | 18,000 | $2,700.00 | 22,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 61,000 | $8,540.00 | 74,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 126,000 | $17,640.00 | 215,800 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 128,000 | $17,920.00 | 147,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 20,000 | $2,800.00 | 80,000 | SEC Form 4 |
Latest Avenue Therapeutics Inc. News
ATXI Breaking Stock News: Dive into ATXI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
2 months ago
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
GlobeNewswire
2 months ago
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
3 months ago
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
GlobeNewswire
3 months ago
Avenue Therapeutics Announces Reverse Stock Split
GlobeNewswire
4 months ago
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
GlobeNewswire
4 months ago
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire
4 months ago
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Compare ATXI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATXI Avenue Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.